RT Journal Article
SR Electronic
T1 Connectome-based predictive modeling of brain pathology and cognition in Autosomal Dominant Alzheimer’s Disease
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.09.01.24312913
DO 10.1101/2024.09.01.24312913
A1 Tripathi, Vaibhav
A1 Fox-Fuller, Joshua
A1 Malotaux, Vincent
A1 Baena, Ana
A1 Felix, Nikole Bonillas
A1 Alvarez, Sergio
A1 Aguillon, David
A1 Lopera, Francisco
A1 Somers, David C
A1 Quiroz, Yakeel T.
YR 2024
UL http://medrxiv.org/content/early/2024/09/03/2024.09.01.24312913.abstract
AB INTRODUCTION Autosomal Dominant Alzheimer’s Disease (ADAD) through genetic mutations can result in near complete expression of the disease. Tracking AD pathology development in an ADAD cohort of Presenilin-1 (PSEN1) E280A carriers’ mutation has allowed us to observe incipient tau tangles accumulation as early as 6 years prior to symptom onset.METHODS Resting-state functional Magnetic Resonance Imaging (fMRI) and Positron-Emission Tomography (PET) scans were acquired in a group of PSEN1 carriers (n=32) and non-carrier family members (n=35). We applied Connectome-based Predictive Modeling (CPM) to examine the relationship between the participant’s functional connectome and their respective tau/amyloid-β levels and cognitive scores (word list recall).RESULTS CPM models strongly predicted tau concentrations and cognitive scores within the carrier group. The connectivity patterns between the temporal cortex, default mode network, and other memory networks were the most informative of tau burden.DISCUSSION These results indicate that resting-state fMRI methods can complement PET methods in early detection and monitoring of disease progression in ADAD.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe COLBOS study was sponsored from grants from the National Institute on Aging (R01AG054671, RF1AG077627).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Institutional Ethics Review Board of the University of Antioquia in Colombia and Massachusetts General Hospital in Boston.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data in the study are available on request from the corresponding author Y.T.Q.